Aliases & Classifications for Ocular Hypotension

Aliases & Descriptions for Ocular Hypotension:

Name: Ocular Hypotension 12 42 14 69
Hypotony of Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:790
ICD10 33 H44.4 H44.40
ICD9CM 35 360.3 360.30
MeSH 42 D015814
UMLS 69 C0028841

Summaries for Ocular Hypotension

MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and mental retardation hypocupremia hypobetalipoproteinemia, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Timolol and Dorzolamide have been mentioned in the context of this disorder. Affiliated tissues include eye and brain.

Related Diseases for Ocular Hypotension

Diseases related to Ocular Hypotension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
id Related Disease Score Top Affiliating Genes
1 primary eye hypotony 11.0
2 mental retardation hypocupremia hypobetalipoproteinemia 10.0 ADRB1 ADRB2
3 ocular hypertension 9.9
4 aplasia cutis congenita recessive 9.9 ADRB1 ADRB2
5 open-angle glaucoma 9.9
6 poikiloderma with neutropenia 9.9 ADRB1 ADRB2
7 branchiootorenal syndrome 9.8 PDE4B PDE4D
8 cataract 9.7
9 diabetic macular edema 9.7
10 leprosy 9.6
11 uveitis 9.6
12 anterior uveitis 9.6
13 epithelial malignant thymoma 9.1 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D

Comorbidity relations with Ocular Hypotension via Phenotypic Disease Network (PDN):


Glaucoma 1, Open Angle, F Pigment Dispersion Syndrome

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension

Symptoms & Phenotypes for Ocular Hypotension

UMLS symptoms related to Ocular Hypotension:


eye manifestations

Drugs & Therapeutics for Ocular Hypotension

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 308)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 4 26839-75-8 33624 5478
2
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
3
Clonidine Approved Phase 4,Phase 1 4205-90-7 2803
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
6
Phenylephrine Approved Phase 4,Phase 1 59-42-7 6041
7
Oxymetazoline Approved Phase 4,Phase 1 1491-59-4 4636
8
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
9
Ephedrine Approved Phase 4,Phase 2,Phase 1 299-42-3 9294
10
Midodrine Approved Phase 4,Phase 2 133163-28-7, 42794-76-3 4195
11
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
14
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
15
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
16
Pseudoephedrine Approved Phase 4,Phase 2,Phase 1 90-82-4 7028
17
Ergonovine Approved Phase 4 60-79-7 443884
18
Carteolol Approved Phase 4 51781-06-7 2583
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
20
Ethanol Approved Phase 4 64-17-5 702
21
Menthol Approved Phase 4 2216-51-5 16666
22
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
23
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
24
Promethazine Approved Phase 4 60-87-7 4927
25 tannic acid Approved, Nutraceutical Phase 4
26 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Adrenergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3,Phase 1
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
32 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Phase 1
33 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Carbonic Anhydrase Inhibitors Phase 4
36 Brimonidine Tartrate Phase 4 70359-46-5
37 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
38 Adjuvants, Anesthesia Phase 4,Phase 1
39 Mydriatics Phase 4,Phase 1
40 Narcotics Phase 4,Phase 3
41 Nasal Decongestants Phase 4,Phase 2,Phase 1
42 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
43 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 1
44 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
45 Sympatholytics Phase 4,Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 3
47 Analgesics, Opioid Phase 4,Phase 3
48 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
49 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
50 Oxytocics Phase 4

Interventional clinical trials:

(show top 50) (show all 143)
id Name Status NCT ID Phase
1 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4
2 Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation Unknown status NCT00326729 Phase 4
3 A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4
4 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4
5 Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Completed NCT00312416 Phase 4
6 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach Completed NCT02135146 Phase 4
7 Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study Completed NCT00707928 Phase 4
8 Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT Completed NCT00790062 Phase 4
9 Study Evaluating Whether the Bispectral Index Prevents Patients at Higher Risk From Being Awake During Surgery and Anesthesia Completed NCT00682825 Phase 4
10 Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery Completed NCT02312999 Phase 4
11 Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction Recruiting NCT02590822 Phase 4
12 Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure Recruiting NCT02203019 Phase 4
13 Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Randomised, Double-blind, Non-inferiority Trial Recruiting NCT03024697 Phase 4
14 REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study Active, not recruiting NCT01424150 Phase 4
15 Clinical Evaluation of CATS Tonometer Prism Not yet recruiting NCT02990169 Phase 4
16 Labour Analgesia: A Comparison Between Two Intrathecal Regimens Not yet recruiting NCT03117595 Phase 4
17 A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension Terminated NCT00046163 Phase 4
18 Ephedrine vs Phenylephrine - ECG Changes Terminated NCT01243970 Phase 4
19 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3
20 Effect of Lowering the Dialysate Sodium on Blood Pressure in Hemodialysis Patients Unknown status NCT00724633 Phase 3
21 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3
22 Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy Completed NCT00315796 Phase 3
23 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3
24 Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants Completed NCT00358748 Phase 3
25 A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Completed NCT01176240 Phase 3
26 Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Completed NCT01522235 Phase 2, Phase 3
27 Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children Completed NCT00405522 Phase 3
28 Efficacy and Safety of Primovist in Chinese Patients Completed NCT00526188 Phase 3
29 Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial Completed NCT01326676 Phase 3
30 Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery Completed NCT00321295 Phase 3
31 Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity Completed NCT01079715 Phase 2, Phase 3
32 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3
33 A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3
34 A Study to Compare the Long-term Outcomes After Two Different Anaesthetics Not yet recruiting NCT03089905 Phase 3
35 Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus Terminated NCT00539409 Phase 2, Phase 3
36 Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Terminated NCT00211224 Phase 3
37 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Withdrawn NCT01560091 Phase 3
38 Aqueous Mushroom Extract and Intraocular Pressure Unknown status NCT01017068 Phase 1, Phase 2
39 A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Completed NCT01123785 Phase 1, Phase 2
40 A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride Completed NCT00426842 Phase 2
41 Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury Completed NCT01874782 Phase 2
42 A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension Completed NCT00522925 Phase 2
43 Acute Effects of Inhaled Treprostinil in Fontan Patients Recruiting NCT02769624 Phase 2
44 Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Recruiting NCT02415608 Phase 2
45 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2
46 Biomarker Guided Therapies in Stage A/B Heart Failure Recruiting NCT02230891 Phase 2
47 Automated Administration of Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia Recruiting NCT02138942 Phase 2
48 a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity Not yet recruiting NCT03038295 Phase 2
49 Intraocular Pressure During Prone Spinal Surgery Terminated NCT00176722 Phase 2
50 Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease Terminated NCT00492531 Phase 2

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Genetic Tests for Ocular Hypotension

Anatomical Context for Ocular Hypotension

MalaCards organs/tissues related to Ocular Hypotension:

39
Eye, Brain

Publications for Ocular Hypotension

Articles related to Ocular Hypotension:

(show top 50) (show all 66)
id Title Authors Year
1
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. ( 25719991 )
2015
2
ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects. ( 24749907 )
2014
3
The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study. ( 25319729 )
2014
4
Impact of ocular hypotensive lipids on clinically significant diabetic macular edema. ( 22267460 )
2012
5
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. ( 21794845 )
2011
6
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. ( 21434594 )
2010
7
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. ( 20148660 )
2010
8
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. ( 20426763 )
2010
9
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. ( 19234340 )
2009
10
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. ( 18992242 )
2009
11
Prolonged ocular hypotension: would ciliary tissue transplantation help. ( 19098698 )
2009
12
Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. ( 19210139 )
2009
13
Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? ( 18460537 )
2008
14
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. ( 17565920 )
2007
15
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. ( 17238805 )
2006
16
Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. ( 16968567 )
2006
17
Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. ( 17056362 )
2006
18
Fadolmidine-induced ocular hypotension in normotensive rabbits. ( 15720782 )
2005
19
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. ( 15006155 )
2004
20
Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. ( 15216404 )
2004
21
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. ( 15037111 )
2004
22
New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. ( 14646172 )
2003
23
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. ( 12676887 )
2003
24
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. ( 14733708 )
2003
25
Cystoid macular edema associated with ocular hypotensive lipids. ( 11860980 )
2002
26
Cystoid macular edema in the era of ocular hypotensive lipids. ( 11915838 )
2002
27
Ocular hypotension induced by electroacupuncture. ( 12222760 )
2002
28
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit. ( 10882008 )
2000
29
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. ( 10614682 )
2000
30
Mechanism of exercise-induced ocular hypotension. ( 10102302 )
1999
31
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. ( 10433858 )
1999
32
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. ( 9851310 )
1998
33
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. ( 9742290 )
1998
34
Ocular hypotension induced by intravitreally injected C-type natriuretic peptide. ( 9533834 )
1998
35
Ocular hypotensive effect of topical ketanserin in timolol users. ( 9085107 )
1997
36
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. ( 9436152 )
1997
37
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. ( 8921215 )
1996
38
Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor. ( 8590276 )
1995
39
Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. ( 7542619 )
1995
40
Centrally mediated ocular hypotension: potential role of imidazoline receptors. ( 7677360 )
1995
41
Ocular hypotension during short- and long-term hypocapnia. ( 19920601 )
1994
42
Correlates of acute exercise-induced ocular hypotension. ( 7928182 )
1994
43
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. ( 7925603 )
1994
44
Long-term visual outcome of ocular hypotension after thermosclerostomy. ( 8488912 )
1993
45
PhXA34-induced ocular hypotension. ( 1463535 )
1992
46
Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. ( 1349879 )
1992
47
Soluble forms of isobutylmethylxanthine enhance the ocular hypotension induced by catecholamines. ( 1722476 )
1991
48
Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. ( 1712310 )
1991
49
Reattachment of the detached ciliary body with suturing for treatment of contusional ocular hypotension. ( 1896179 )
1991
50
The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. ( 2322152 )
1990

Variations for Ocular Hypotension

Expression for Ocular Hypotension

Search GEO for disease gene expression data for Ocular Hypotension.

Pathways for Ocular Hypotension

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2
Show member pathways
12.47 ADRB1 ADRB2 PDE4B PDE4C PDE4D
3
Show member pathways
12.27 PDE4B PDE4C PDE4D
4
Show member pathways
12.2 PDE4B PDE4C PDE4D
5 12.18 ADRB1 ADRB2 PDE4B
6
Show member pathways
12.12 ADRB2 PDE4B PDE4C PDE4D
7
Show member pathways
12.05 ADRB1 ADRB2 PDE4B PDE4D
8
Show member pathways
11.9 ADRB1 ADRB2 HTR2B
9 11.71 ADRB1 ADRB2 PDE4B
10
Show member pathways
11.66 ADRB1 ADRB2 PDE4B PDE4C PDE4D
11
Show member pathways
11.64 ADRB1 ADRB2 HTR2B
12
Show member pathways
11.5 PDE4B PDE4C PDE4D
13 11.38 ADRB1 ADRB2
14 11.3 ADRB1 ADRB2
15 11.27 ADRB1 ADRB2
16 11.19 ADRB1 ADRB2 PDE4B PDE4C PDE4D
17 10.84 ADRB1 ADRB2

GO Terms for Ocular Hypotension

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 8.62 PDE4B PDE4D

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.8 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2 cellular response to lipopolysaccharide GO:0071222 9.59 PDE4B PDE4D
3 neutrophil chemotaxis GO:0030593 9.58 PDE4B PDE4D
4 positive regulation of interferon-gamma production GO:0032729 9.58 PDE4B PDE4D
5 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.57 ADRB1 ADRB2
6 response to cold GO:0009409 9.56 ADRB1 ADRB2
7 activation of adenylate cyclase activity GO:0007190 9.55 ADRB1 ADRB2
8 brown fat cell differentiation GO:0050873 9.54 ADRB1 ADRB2
9 smooth muscle contraction GO:0006939 9.52 HTR2B PDE4D
10 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.51 ADRB1 ADRB2
11 positive regulation of interleukin-2 production GO:0032743 9.49 PDE4B PDE4D
12 cellular response to epinephrine stimulus GO:0071872 9.48 PDE4B PDE4D
13 negative regulation of multicellular organism growth GO:0040015 9.46 ADRB1 ADRB2
14 regulation of cardiac muscle cell contraction GO:0086004 9.43 PDE4B PDE4D
15 diet induced thermogenesis GO:0002024 9.4 ADRB1 ADRB2
16 adrenergic receptor signaling pathway GO:0071875 9.37 ADRB2 PDE4D
17 vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
18 heat generation GO:0031649 9.16 ADRB1 ADRB2
19 negative regulation of relaxation of cardiac muscle GO:1901898 8.96 PDE4B PDE4D
20 cAMP catabolic process GO:0006198 8.8 PDE4B PDE4C PDE4D

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.61 ADRB1 ADRB2 HTR2B
2 ion channel binding GO:0044325 9.48 PDE4B PDE4D
3 drug binding GO:0008144 9.46 HTR2B PDE4D
4 cAMP binding GO:0030552 9.4 PDE4B PDE4D
5 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.37 PDE4B PDE4D
6 adrenergic receptor activity GO:0004935 9.32 ADRB1 ADRB2
7 epinephrine binding GO:0051379 9.26 ADRB1 ADRB2
8 norepinephrine binding GO:0051380 9.16 ADRB1 ADRB2
9 phosphoric diester hydrolase activity GO:0008081 9.13 PDE4B PDE4C PDE4D
10 3,5-cyclic-AMP phosphodiesterase activity GO:0004115 8.8 PDE4B PDE4C PDE4D

Sources for Ocular Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....